This prospective cohort study aims to investigate factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP) with and without lifetime cannabis use (LCU). Participants hospitalized at Elazığ Mental Health and Diseases Hospital who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for MP will be included. Participants will be divided into two groups based on the presence or absence of LCU. Psychiatric symptoms and clinical characteristics will be assessed weekly during an eight-week inpatient follow-up period using standardized psychometric instruments. The study aims to determine whether LCU influences the course and severity of psychiatric symptoms in MP and to identify environmental, individual, and familial factors associated with symptom progression.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Insight Assessment Scale (IAS)
Timeframe: It will be administered once a week for eight weeks.
Addiction Profile Index Clinical-Practitioner Form (API-C)
Timeframe: It will be administered once a week for eight weeks.
Positive and Negative Syndrome Scale (PANSS)
Timeframe: It will be administered once a week for eight weeks.
Global Assessment Scale (GAS)
Timeframe: It will be administered once a week for eight weeks.
Pittsburgh Sleep Quality Index (PSQI)
Timeframe: It will be administered once a week for eight weeks.
Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist